Proteomics (ASX: PIQ) — Company Overview, News & Financial Data
Proteomics is an Australian biotechnology company specializing in proteomics research and services for drug discovery and diagnosis.
Proteomics
Proteomics is a medical technology and precision diagnostics company focused on the discovery and commercialisation of predictive protein-based biomarker tests. The company utilizes mass spectrometry-based proteomics technology to map structural and functional protein changes for early disease diagnosis and monitoring. Its proprietary diagnostic portfolio includes blood tests for predicting diabetes-related chronic kidney disease, as well as diagnostic panels under development for endometriosis and esophageal cancer. Operating an accredited analytical laboratory in Perth, Western Australia, the organization also provides specialized contract research, mass spectrometry analytical services, and diagnostic kit distribution across international markets.
Snapshot
Operations
Products and/or services of Proteomics
- Diabetic Kidney Disease Diagnostics: Predictive blood testing services and diagnostic immunoassay kits designed to assess predicting risks of diabetic kidney disease up to four years prior to clinical symptoms, distributed through international diagnostic laboratory partnerships.
- Endometriosis Diagnostic Testing: Non-invasive blood-based biomarker diagnostic tests developed to enable early clinical detection of endometriosis, reducing diagnosis timelines for patients through targeted protein biomarker panel analysis conducted across accredited clinical laboratory facilities.
- Esophageal Cancer Diagnostics: Diagnostic blood tests utilizing protein biomarker panels to detect specific molecular changes, assisting clinicians in screening and ruling out esophageal adenocarcinoma in symptomatic patients prior to invasive endoscopic procedures.
- Oxidative Stress Assays: Specialized biomarker testing technology and analytical assays used for measuring oxidative stress levels in biological samples, supporting research applications, clinical trial studies, and veterinary health monitoring across agricultural and healthcare sectors.
- Proteomics Analytical Services: Mass spectrometry-based analytical contract research services providing protein identification, complex structural characterization, novel biomarker discovery, and quality control testing for global biotechnology companies, academic research institutions, and pharmaceutical organizations.
- Clinical Laboratory Testing Services: High-throughput diagnostic processing and specialized biomarker analytical testing performed at a centralized NATA-accredited laboratory facility in Perth, Western Australia, supporting regional blood collection networks and diagnostic partners.
Proteomics executive team
- David N. MorrisMD, CEO & Director
- Timothy LuscombeCFO & Company Secretary
- Scott BringansChief Scientific Officer
- Phillip PratherChief Commercial Officer
- Kirsten PetersDirector of Clinical Science
Latest news about Proteomics
Proteomics International secures Australian patent
AustraliaProteomics International secures US patent until 2041
AustraliaProteomics International secures Canadian patent for PromarkerEso
AustraliaProteomics International names new CEO and Managing Director
AustraliaProteomics International secures US patent for PromarkerEso blood test
Australia
Recent announcements
What Proteomics (PIQ) has told the market, newest first.
- PromarkerEndo Validation and Refinement CompletePrice sensitive
Key financials
Reported results for Proteomics, in AUD.
- Market cap
- 19.4M
- Revenue (TTM)
- 3.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.1
- Dividend yield
- —
- Profit margin
- -254.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 278K | -11.9M | -8.6M | |
| 960.4K | -10.6M | -8.1M | |
| 892.1K | -9.1M | -6.4M | |
| 730.3K | -6.4M | -6.2M |